- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04246047
Оценка эффективности и безопасности белантамаба мафодотина, бортезомиба и дексаметазона по сравнению с даратумумабом, бортезомибом и дексаметазоном у участников с рецидивирующей/рефрактерной множественной миеломой (DREAMM 7)
DREAMM 7: Многоцентровое открытое рандомизированное исследование III фазы по оценке эффективности и безопасности комбинации белантамаба, мафодотина, бортезомиба и дексаметазона (B-Vd) по сравнению с комбинацией даратумумаба, бортезомиба и дексаметазона (D-Vd). ) у участников с рецидивирующей/рефрактерной множественной миеломой
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Расширенный доступ
Контакты и местонахождение
Места учебы
-
-
New South Wales
-
Camperdown, New South Wales, Австралия, 2050
- GSK Investigational Site
-
Liverpool, New South Wales, Австралия, 2170
- GSK Investigational Site
-
Newcastle, New South Wales, Австралия, 2298
- GSK Investigational Site
-
St Leonards, New South Wales, Австралия, 2065
- GSK Investigational Site
-
Wollongong, New South Wales, Австралия, 2500
- GSK Investigational Site
-
-
Queensland
-
Benowa, Queensland, Австралия, 4217
- GSK Investigational Site
-
Herston, Queensland, Австралия, 4029
- GSK Investigational Site
-
-
South Australia
-
Ashford, South Australia, Австралия, 5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill, Victoria, Австралия, 3128
- GSK Investigational Site
-
Heidelberg, Victoria, Австралия, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Австралия, 3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch, Western Australia, Австралия, 6150
- GSK Investigational Site
-
Nedlands, Western Australia, Австралия, 6009
- GSK Investigational Site
-
-
-
-
-
Roeselare, Бельгия, 8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette, Brussels Capital, Бельгия, 1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert, Brussels Capital, Бельгия, 1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Бельгия, 9000
- GSK Investigational Site
-
-
-
-
-
Joinville, Бразилия, 89201-260
- GSK Investigational Site
-
Natal, Бразилия, 59075-740
- GSK Investigational Site
-
Rio de Janeiro, Бразилия, 22775001
- GSK Investigational Site
-
São Paulo, Бразилия, 04537-080
- GSK Investigational Site
-
São Paulo, Бразилия, 05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Бразилия, 88020-210
- GSK Investigational Site
-
-
-
-
-
Cologne, Германия, 50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Германия, 89081
- GSK Investigational Site
-
-
Bavaria
-
München, Bavaria, Германия, 81377
- GSK Investigational Site
-
Würzburg, Bavaria, Германия, 97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Германия, 40225
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Германия, 07747
- GSK Investigational Site
-
-
-
-
-
Athens, Греция, 11528
- GSK Investigational Site
-
Thessaloniki, Греция, 54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli, East Macedonia and Thrace, Греция, 681 00
- GSK Investigational Site
-
-
-
-
-
Jerusalem, Израиль, 91120
- GSK Investigational Site
-
Kfar Saba, Израиль, 44281
- GSK Investigational Site
-
Ramat Gan, Израиль, 52621
- GSK Investigational Site
-
Tel Aviv, Израиль, 64239
- GSK Investigational Site
-
-
-
-
-
Barcelona, Испания, 08035
- GSK Investigational Site
-
Barcelona, Испания, 08916
- GSK Investigational Site
-
Cáceres, Испания, 10003
- GSK Investigational Site
-
Gijón, Испания, 33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega, Испания, 08908
- GSK Investigational Site
-
MOstoles Madrid, Испания, 28933
- GSK Investigational Site
-
Madrid, Испания, 28007
- GSK Investigational Site
-
Madrid, Испания, 31008
- GSK Investigational Site
-
Murcia, Испания, 30008
- GSK Investigational Site
-
PamplonaNavarra, Испания, 31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Испания, 28223
- GSK Investigational Site
-
Salamanca, Испания, 37007
- GSK Investigational Site
-
-
-
-
-
Bergamo, Италия, 24127
- GSK Investigational Site
-
Bologna, Италия, 40138
- GSK Investigational Site
-
Brescia, Италия, 25123
- GSK Investigational Site
-
Catania, Италия, 95123
- GSK Investigational Site
-
Meldola FC, Италия, 47014
- GSK Investigational Site
-
Milan, Италия, 20133
- GSK Investigational Site
-
Ravenna, Италия, 48121
- GSK Investigational Site
-
Roma, Италия, 00168
- GSK Investigational Site
-
Siena, Италия, 53100
- GSK Investigational Site
-
Torino, Италия, 10126
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Канада, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London, Ontario, Канада, N6A 5W9
- GSK Investigational Site
-
Toronto, Ontario, Канада, M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Канада, H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Beijing, Китай, 100191
- GSK Investigational Site
-
Beijing, Китай, 100020
- GSK Investigational Site
-
Changchun, Китай, 130012
- GSK Investigational Site
-
Guangzhou, Китай, 510060
- GSK Investigational Site
-
Guangzhou, Китай, 510515
- GSK Investigational Site
-
Hangzhou, Китай, 310003
- GSK Investigational Site
-
Jinan, Китай, 250012
- GSK Investigational Site
-
Nanjing, Китай, 210008
- GSK Investigational Site
-
Shenyang, Китай, 110001
- GSK Investigational Site
-
Suzhou, Китай, 215006
- GSK Investigational Site
-
Tianjin, Китай, 300020
- GSK Investigational Site
-
Zhengzhou, Китай, 450052
- GSK Investigational Site
-
-
-
-
-
Groningen, Нидерланды, 9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht, South Holland, Нидерланды, 3318 AT
- GSK Investigational Site
-
-
-
-
-
Christchurch, Новая Зеландия, 8011
- GSK Investigational Site
-
Dunedin, Новая Зеландия, 9054
- GSK Investigational Site
-
Takapuna Auckland, Новая Зеландия, 1309
- GSK Investigational Site
-
Wellington, Новая Зеландия, 6021
- GSK Investigational Site
-
-
-
-
-
Chorzów, Польша, 41-500
- GSK Investigational Site
-
Krakow, Польша, 30510
- GSK Investigational Site
-
Lodz, Польша, 93-513
- GSK Investigational Site
-
Lublin, Польша, 20-081
- GSK Investigational Site
-
Lublin, Польша, 20-090
- GSK Investigational Site
-
Nowy Sącz, Польша, 33-300
- GSK Investigational Site
-
Poznan, Польша, 60-569
- GSK Investigational Site
-
Warsaw, Польша, 02-781
- GSK Investigational Site
-
-
-
-
-
Moscow, Россия, 125284
- GSK Investigational Site
-
Nizhny Novgorod, Россия, 603126
- GSK Investigational Site
-
Novosibirsk, Россия, 630087
- GSK Investigational Site
-
Saint Petersburg, Россия, 191024
- GSK Investigational Site
-
Saint Petersburg, Россия, 197 089
- GSK Investigational Site
-
Samara, Россия, 443021
- GSK Investigational Site
-
Saratov, Россия, 410028
- GSK Investigational Site
-
Ufa, Россия, 450083
- GSK Investigational Site
-
-
-
-
-
Bournemouth, Соединенное Королевство, BH7 7DW
- GSK Investigational Site
-
Cardiff, Соединенное Королевство, CF14 4XW
- GSK Investigational Site
-
Dundee, Соединенное Королевство, DD1 9SY
- GSK Investigational Site
-
Leicester, Соединенное Королевство, LE1 5WW
- GSK Investigational Site
-
London, Соединенное Королевство, W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent, Соединенное Королевство, ST4 6QG
- GSK Investigational Site
-
Sutton, Соединенное Королевство, SM2 5PT
- GSK Investigational Site
-
-
-
-
Arizona
-
Yuma, Arizona, Соединенные Штаты, 85364
- GSK Investigational Site
-
-
Kansas
-
Mission, Kansas, Соединенные Штаты, 66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver, North Carolina, Соединенные Штаты, 80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash, Ohio, Соединенные Штаты, 45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler, Texas, Соединенные Штаты, 75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke, Virginia, Соединенные Штаты, 24014
- GSK Investigational Site
-
-
-
-
-
Amiens, Франция, 80054
- GSK Investigational Site
-
Caen, Франция, 14033
- GSK Investigational Site
-
Nice, Франция, 06200
- GSK Investigational Site
-
Paris, Франция, 75651
- GSK Investigational Site
-
Rennes, Франция, 35033
- GSK Investigational Site
-
-
-
-
-
Brno, Чехия, 625 00
- GSK Investigational Site
-
Hradec Králové, Чехия, 500 05
- GSK Investigational Site
-
Ostrava, Чехия, 708 52
- GSK Investigational Site
-
Prague, Чехия, 128 08
- GSK Investigational Site
-
-
-
-
-
Pusan, Южная Корея, 49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, Южная Корея, 13620
- GSK Investigational Site
-
Seoul, Южная Корея, 06351
- GSK Investigational Site
-
Seoul, Южная Корея, 06591
- GSK Investigational Site
-
Ulsan, Южная Корея, 44033
- GSK Investigational Site
-
-
-
-
-
Aichi, Япония, 467-8602
- GSK Investigational Site
-
Aichi, Япония, 441-8570
- GSK Investigational Site
-
Aomori, Япония, 030-8553
- GSK Investigational Site
-
Ehime, Япония, 790-8524
- GSK Investigational Site
-
Fukuoka, Япония, 806-8501
- GSK Investigational Site
-
Fukuoka, Япония, 807-8555
- GSK Investigational Site
-
Fukuoka, Япония, 810-8563
- GSK Investigational Site
-
Fukuoka, Япония, 815-8555
- GSK Investigational Site
-
Gifu, Япония, 503-8502
- GSK Investigational Site
-
Gunma, Япония, 377-0280
- GSK Investigational Site
-
Hyōgo, Япония, 670-8540
- GSK Investigational Site
-
Kanagawa, Япония, 247-8533
- GSK Investigational Site
-
Kanagawa, Япония, 221-0855
- GSK Investigational Site
-
Kochi, Япония, 781-8555
- GSK Investigational Site
-
Nagano, Япония, 392-8510
- GSK Investigational Site
-
Okayama, Япония, 701-1192
- GSK Investigational Site
-
Osaka, Япония, 545-8586
- GSK Investigational Site
-
Osaka, Япония, 530-0012
- GSK Investigational Site
-
Shizuoka, Япония, 411-8777
- GSK Investigational Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Белантамаб мафодотин и бортезомиб плюс дексаметазон (группа А)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
Активный компаратор: Даратумумаб и бортезомиб плюс дексаметазон (группа B)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free Survival (PFS)
Временное ограничение: Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Количество участников с аномальными показателями зрения при офтальмологическом обследовании
Временное ограничение: До 73 месяцев
|
До 73 месяцев
|
|
|
Complete Response Rate (CRR)
Временное ограничение: Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
Временное ограничение: Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
Временное ограничение: Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
Временное ограничение: Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
Временное ограничение: Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
Временное ограничение: Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
Временное ограничение: Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Временное ограничение: Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
Временное ограничение: Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
Временное ограничение: Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
Временное ограничение: Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Временное ограничение: Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
Временное ограничение: Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Временное ограничение: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Временное ограничение: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Временное ограничение: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Временное ограничение: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
Временное ограничение: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Временное ограничение: Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Временное ограничение: Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
Временное ограничение: Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: GSK Clinical Trials, GlaxoSmithKline
Публикации и полезные ссылки
Общие публикации
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Новообразования
- Заболевания иммунной системы
- Новообразования по гистологическому типу
- Гематологические заболевания
- Лимфопролиферативные заболевания
- Иммунопролиферативные заболевания
- Новообразования, Плазматические клетки
- Нарушения гемостаза
- Парапротеинемии
- Нарушения белков крови
- Геморрагические расстройства
- Гемики и лимфатические заболевания
- Множественная миелома
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Полициклические соединения
- Неорганические химические вещества
- Беременные
- Беременные
- Стероиды
- Соединения слитого кольца
- Стероиды, фторированные
- Bergyadienetriols
- Бороновые кислоты
- Кислоты, некарбоновая
- Кислоты
- Бор соединения
- Пиразины
- Бортезомиб
- Дексаметазон
- даратумумаб
- Белантамаб мафодотин
Другие идентификационные номера исследования
- 207503
- 2018 (Грант/контракт NIH США)
- 2018-003993-29 (Идентификатор реестра: EudraCT (EU))
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .